Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Sedaghat, Ahmad R ^a   Siliciano, Robert F ^a,b   Wilke, Claus O ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CELL KINETICS; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; MATHEMATICAL MODEL; MEDICAL RECORD REVIEW; NONHUMAN; VIRUS REACTIVATION; VIRUS REPLICATION; BIOLOGICAL MODEL; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 39749112383     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-2     Document Type: Article

References (70)

1. Chun TW Finzi D Margolick J Chadwick K Schwartz D Siliciano RF: In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med 1995, 1:1284-1290. 10.1038/nm1295-1284 7489410
2. Chun TW Stuyver L Mizell SB Ehler LA Mican JA Baseler M Lloyd AL Nowak MA Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197. 24285 9371822 10.1073/pnas.94.24.13193
3. Chun TW Carruth L Finzi D Shen X DiGiuseppe JA Taylor H Hermankova M Chadwick K Margolick J Quinn TC Kuo YH Brookmeyer R Zeiger MA Barditch-Crovo P Siliciano RF: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188. 10.1038/387183a0 9144289
4. Finzi D Hermankova M Pierson T Carruth LM Buck C Chaisson RE Quinn TC Chadwick K Margolick J Brookmeyer R Gallant J Markowitz M Ho DD Richman DD Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300. 10.1126/science.278.5341.1295 9360927
5. Hermankova M Siliciano JD Zhou Y Monie D Chadwick K Margolick JB Quinn TC Siliciano RF: Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 2003, 77:7383-7392. 164778 12805437 10.1128/ JVI.77.13.7383-7392.2003
6. Lassen KG Bailey JR Siliciano RF: Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 2004, 78:9105-9114. 506937 15308706 10.1128/ JVI.78.17.9105-9114.2004
7. Brooks DG Hamer DH Arlen PA Gao L Bristol G Kitchen CM Berger EA Zack JA: Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003, 19:413-423. 10.1016/S1074-7613(03)00236-X 14499116
8. Finzi D Blankson J Siliciano JD Margolick JB Chadwick K Pierson T Smith K Lisziewicz J Lori F Flexner C Quinn TC Chaisson RE Rosenberg E Walker B Gange S Gallant J Siliciano RF: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517. 10.1038/8394 10229227
9. Siliciano JD Kajdas J Finzi D Quinn TC Chadwick K Margolick JB Kovacs C Gange SJ Siliciano RF; Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003, 9:727-728. 10.1038/nm880 12754504
10. Chun TW Nickle DC Justement JS Large D Semerjian A Curlin ME O'Shea MA Hallahan CW Daucher M Ward DJ Moir S Mullins JI Kovacs C Fauci AS: HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005, 115:3250-3255. 1265878 16276421 10.1172/JCI26197
11. Dornadula G Zhang H VanUitert B Stern J Livornese L Jr Ingerman MJ Witek J Kedanis RJ Natkin J DeSimone J Pomerantz RJ: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627-1632. 10.1001/jama.282.17.1627 10553788
12. Frenkel LM Wang Y Learn GH McKernan JL Ellis GM Mohan KM Holte SE De Vange SM Pawluk DM Melvin AJ Lewis PF Heath LM Beck IA Mahalanabis M Naugler WE Tobin NH Mullins JI: Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 2003, 77:5721-5730. 154035 12719565 10.1128/JVI.77.10.5721-5730.2003
13. Furtado MR Callaway DS Phair JP Kunstman KJ Stanton JL Macken CA Perelson AS Wolinsky SM: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622. 10.1056/ NEJM199905273402102 10341273
14. Havlir DV Strain MC Clerici M Ignacio C Trabattoni D Ferrante P Wong JK: Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003, 77:11212-11219. 224988 14512569 10.1128/JVI.77.20.11212-11219.2003
15. Imamichi H Crandall KA Natarajan V Jiang MK Dewar RL Berg S Gaddam A Bosche M Metcalf JA Davey RT Jr Lane HC: Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001, 183:36-50. 10.1086/ 317641 11106537
16. Natarajan V Bosche M Metcalf JA Ward DJ Lane HC Kovacs JA: HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 1999, 353:119-120. 10.1016/ S0140-6736(05)76156-0 10023903
17. Tobin NH Learn GH Holte SE Wang Y Melvin AJ McKernan JL Pawluk DM Mohan KM Lewis PF Mullins JI Frenkel LM: Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol 2005, 79:9625-9634. 1181593 16014925 10.1128/ JVI.79.15.9625-9634.2005
18. Zhang L Ramratnam B Tenner-Racz K He Y Vesanen M Lewin S Talal A Racz P Perelson AS Korber BT Markowitz M Ho DD: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613. 10.1056/NEJM199905273402101 10341272
19. Ramratnam B Mittler JE Zhang L Boden D Hurley A Fang F Macken CA Perelson AS Markowitz M Ho DD; The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6:82-85. 10.1038/71577 10613829
20. Ramratnam B Ribeiro R He T Chung C Simon V Vanderhoeven J Hurley A Zhang L Perelson AS Ho DD Markowitz M: Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004, 35:33-37. 10.1097/00126334-200401010-00004 14707789
21. Hermankova M Ray SC Ruff C Powell-Davis M Ingersoll R D'Aquila RT Quinn TC Siliciano JD Siliciano RF Persaud D: HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 2001, 286:196-207. 10.1001/jama.286.2.196 11448283
22. Siliciano JD Siliciano RF: A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004, 54:6-9. 10.1093/jac/dkh292 15163657
23. Strain MC Gunthard HF Havlir DV Ignacio CC Smith DM Leigh-Brown AJ Macaranas TR Lam RY Daly OA Fischer M Opravil M Levine H Bacheler L Spina CA Richman DD Wong JK: Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003, 100:4819-4824. 153639 12684537 10.1073/pnas.0736332100
24. Nettles RE Kieffer TL Kwon P Monie D Han Y Parsons T Cofrancesco J Jr Gallant JE Quinn TC Jackson B Flexner C Carson K Ray S Persaud D Siliciano RF: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293:817-829. 10.1001/jama.293.7.817 15713771
25. Persaud D Siberry GK Ahonkhai A Kajdas J Monie D Hutton N Watson DC Quinn TC Ray SC Siliciano RF: Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004, 78:968-979. 368798 14694128 10.1128/JVI.78.2.968-979.2004
26. Kieffer TL Finucane MM Nettles RE Quinn TC Broman KW Ray SC Persaud D Siliciano RF: Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004, 189:1452-1465. 10.1086/382488 15073683
27. Sedaghat AR Siliciano JD Brennan TP Wilke CO Siliciano RF; Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog 2007, 3:e122. 1959378 17784786 10.1371/ journal.ppat.0030122
28. Bonhoeffer S May RM Shaw GM Nowak MA: Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997, 94:6971-6976. 21269 9192676 10.1073/ pnas.94.13.6971
29. Nowak MA Bonhoeffer S Shaw GM May RM: Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 1997, 184:203-217. 10.1006/jtbi.1996.0307 9059598
30. Perelson AS Neumann AU Markowitz M Leonard JM Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586. 10.1126/ science.271.5255.1582 8599114
31. Perelson AS Essunger P Cao Y Vesanen M Hurley A Saksela K Markowitz M Ho DD: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191. 10.1038/387188a0 9144290
32. De Boer RJ Perelson AS: Target cell limited and immune control models of HIV infection: A comparison. J Theor Biol 1998, 190:201-214. 10.1006/ jtbi.1997.0548 9514649
33. Rouzine IM Sergeev RA Glushtsov AI: Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc Natl Acad Sci USA 2006, 103:666-671. 1334670 16407101 10.1073/pnas.0510016103
34. Wick D Self SG: What's the matter with HIV-directed killer T cells? J Theor Biol 2002, 219:19-31. 12392972
35. Nowak MA May RM Anderson RM: The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. AIDS 1990, 4:1095-1103. 10.1097/00002030-199011000-00007 2282182
36. Ribeiro RM Mohri H Ho DD Perelson AS: In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?. Proc Natl Acad Sci USA 2002, 99:15572-15577. 137758 12434018 10.1073/pnas.242358099
37. Grossman Z Meier-Schellersheim M Sousa AE Victorino RM Paul WE: CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause?. Nat Med 2002, 8:319-323. 10.1038/nm0402-319 11927927
38. Krakauer DC Nowak M: T-cell inBuced pathogenesis in HIV: bystander effects and latent infection. Proc Biol Sci 1999, 266:1069-1075. 1689939 10380683 10.1098/rspb.1999.0745
39. Kim H Perelson AS: Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol 2006, 2(10):e135. 1599767 17040122 10.1371/journal.pcbi.0020135
40. Bonhoeffer S Coffin JM Nowak MA: Human immunodeficiency virus drug therapy and virus load. J Virol 1997, 71:3275-3278. 191463 9060694
41. Pierson T McArthMr J Siliciano RF: Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000, 18:665-708. 10.1146/ annurev.immunol.18.1.665 10837072
42. Mohri H Bonhoeffer S Monard S Perelson AS Ho DD; Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 1998, 279:1223-1227. 10.1126/science.279.5354.1223 9469816
43. Kovacs JA Lempicki RA Sidorov IA Adelsberger JW Herpin B Metcalf JA Sereti I Polis MA Davey RT Tavel J Falloon J Stevens R Lambert L Dewar R Schwartzentruber DJ Anver MR Baseler MW Masur H Dimitrov DS Lane HC: Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001, 194:1731-1741. 10.1084/jem.194.12.1731 11748275
44. Davey RT Jr Bhat N Yoder C Chun TW Metcalf JA Dewar R Natarajan V Lempicki RA Adelsberger JW Miller KD Kovacs JA Polis MA Walker RE Falloon J Masur H Gee D Baseler M Dimitrov DS Fauci AS Lane HC: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999, 96:15109-15114. 24781 10611346 10.1073/pnas.96.26.15109
45. Wei X Ghosh SK Taylor ME Johnson VA Emini EA Deutsch P Lifson JD Bonhoeffer S Nowak MA Hahn BH: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122. 10.1038/373117a0 7529365
46. Muller V Vigueras-Gomez JF Bonhoeffer S: Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. J Virol 2002, 76:8963-8965. 136417 12163616 10.1128/ JVI.76.17.8963-8965.2002
47. Maldarelli F Palmer S King MS Wiegand A Polis MA Mican J Kovacs JA Davey RT Rock-Kress D Dewar R Liu S Metcalf JA Rehm C Brun SC Hanna GJ Kempf DJ Coffin JM Mellors JW: ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007, 3:e46. 1847689 17411338 10.1371/journal.ppat.0030046
48. Sereti I Herpin B Metcalf JA Stevens R Baseler MW Hallahan CW Kovacs JA Davey RT: Lane HC CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001, 15:1765-1775. 10.1097/00002030-200109280-00004 11579237
49. Kovacs JA Vogel S Metcalf JA Baseler M Stevens R Adelsberger J Lempicki R Hengel RL Sereti I Lambert L Dewar RL Davey RT Jr Walker RE Falloon J Polis MA Masur H Lane HC: Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol 2001, 31:1351-1360. 10.1002/ 1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9 11465092
50. Lehrman G Hogue IB Palmer S Jennings C Spina CA Wiegand A Landay AL Coombs RW Richman DD Mellors JW Coffin JM Bosch RJ Margolis DM: Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005, 366:549-555. 1894952 16099290 10.1016/S0140-6736(05)67098-5
51. van Praag RM Prins JM Roos MT Schellekens PT Ten B I Yong SL Schuitemaker H Eerenberg AJ Jurriaans S de WF Fox CH Goudsmit J Miedema F Lange JM: OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001, 21:218-226. 10.1023/A:1011091300321 11403229
52. Williams SA Chen LF Kwon H Fenard D Bisgrove D Verdin E Greene WC; Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004, 279:42008-42017. 10.1074/jbc.M402124200 15284245
53. Persaud D Pierson T Ruff C Finzi D Chadwick KR Margolick JB Ruff A Hutton N Ray S Siliciano RF; A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000, 105:995-1003. 377486 10749578
54. Ruff CT Ray SC Kwon P Zinn R Pendleton A Hutton N Ashworth R Gange S Quinn TC Siliciano RF Persaud DL: Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002, 76:9481-9492. 136462 12186930 10.1128/JVI.76.18.9481-9492.2002
55. Bailey JR Sedaghat AR Kieffer T Brennan T Lee PK Wind-Rotolo M Haggerty CM Kamireddi AR Liu Y Lee J Persaud D Gallant JE Cofrancesco J Jr Quinn TC Wilke CO Ray SC Siliciano JD Nettles RE Siliciano RF: Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells. J Virol 2006, 80:6441-6457. 1488985 16775332 10.1128/JVI.00591-06
56. Bajaria SH Webb G Cloyd M Kirschner D: Dynamics of naive and memory CD4+ T lymphocytes in HIV-1 disease progression. J Acquir Immune Defic Syndr 2002, 30:41-58. 10.1097/00126334-200205010-00006 12048362
57. Crowe S Zhu T Muller WA: The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003, 74:635-641. 10.1189/jlb.0503204 12960232
58. Schrager LK D'Souza MP; Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998, 280:67-71. 10.1001/jama.280.1.67 9660366
59. Coffin JM: HIV population dInamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489. 10.1126/ science.7824947 7824947
60. Gulick RM Ribaudo HJ Shikuma CM Lalama C Schackman BR Meyer WA III Acosta EP Schouten J Squires KE Pilcher CD Murphy RL Koletar SL Carlson M Reichman RC Bastow B Klingman KL Kuritzkes DR: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA 2006, 296:769-781. 10.1001/ jama.296.7.769 16905783
61. Swindells S DiRienzo AG Wilkin T Fletcher CV Margolis DM Thal GD Godfrey C Bastow B Ray MG Wang H Coombs RW McKinnon J Mellors JW: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006, 296:806-814. 10.1001/jama.296.7.806 16905786
62. Nunnari G Pomerantz RJ; IL-7 as a potential therapy for HIV-1-infected individuals. Expert Opin Biol Ther 2005, 5:1421-1426. 10.1517/ 14712598.5.11.1421 16255646
63. Wang FX Xu Y Sullivan J Souder E Argyris EG Acheampong EA Fisher J Sierra M Thomson MM Najera R Frank I Kulkosky J Pomerantz RJ Nunnari G; IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005, 115:128-137. 539197 15630452 10.1172/ JCI200522574
64. Kulkosky J Culnan DM Roman J Dornadula G Schnell M Boyd MR Pomerantz RJ: Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001, 98:3006-3015. 10.1182/ blood.V98.10.3006 11698284
65. Perelson AS: Modelling viral and immune system dynamics. Nat Rev Immunol 2002, 2:28-36. 10.1038/nri700 11905835
66. Nelson PW Perelson AS: Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci 2002, 179:73-94. 10.1016/ S0025-5564(02)00099-8 12047922
67. Dixit NM Perelson AS: HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci USA 2005, 102:8198-8203. 1149399 15928092 10.1073/pnas.0407498102
68. Haase AT Henry K Zupancic M Sedgewick G Faust RA Melroe H Cavert W Gebhard K Staskus K Zhang ZQ Dailey PJ Balfour HH Jr Erice A Perelson AS: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-989. 10.1126/science.274.5289.985 8875941
69. Cavert W Notermans DW Staskus K Wietgrefe SW Zupancic M Gebhard K Henry K Zhang ZQ Mills R McDade H Schuwirth CM Goudsmit J Danner SA Haase AT: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964. 10.1126/science.276.5314.960 9139661
70. Ho DD Neumann AU Perelson AS Chen W Leonard JM Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126. 10.1038/373123a0 7816094